Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy

Brain

Volumn 133, Issue 8, 2010, Pages 2410-2425

  Lehéricy, Stéphane ^a,b,c   Hartmann, Andreas ^b,c,d   Lannuzel, Annie ^e   Galanaud, Damien ^a,b,c   Delmaire, Christine ^a,f   Bienaimée, Marie Josée ^a   Jodoin, Nicolas ^c,d   Roze, Emmanuel ^c,d   Gaymard, Bertrand ^b,c,d   Vidailhet, Marie ^b,c,d  

^a Centre de NeuroImagerie de Recherche CENIR   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Federation des Maladies du Systeme Nerveux   (France)

^e Centre Hospitalier Universitaire Pointe a Pitre   (Guadeloupe)

^f Service de Neuroradiologie   (France)

Author keywords

Diffusion tensor imaging; Guadeloupean parkinsonism; Magnetic resonance spectroscopy; Voxel based morphometry

Indexed keywords

CREATININE; N ACETYLASPARTIC ACID; ASPARTIC ACID; N-ACETYLASPARTATE;

ADRENAL CORTEX ATROPHY; AGED; ARTICLE; BASAL GANGLION; BRAIN STEM; CARIBBEAN ISLANDS; CEREBELLUM; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE DURATION; FEMALE; GRAY MATTER; HALLUCINATION; HUMAN; INSULA; LIMBIC CORTEX; MALE; MESENCEPHALON; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL LOBE; ORBITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TEMPORAL LOBE; VOXEL BASED MORPHOMETRY; WHITE MATTER; ANALOGS AND DERIVATIVES; BRAIN; CASE CONTROL STUDY; COGNITIVE DEFECT; COMPLICATION; DEVICES; GUADELOUPE; IMAGE PROCESSING; METABOLISM; PARKINSONISM; PATHOLOGY; PROCEDURES;

AGED; ASPARTIC ACID; BRAIN; CASE-CONTROL STUDIES; COGNITION DISORDERS; CREATININE; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; DIFFUSION TENSOR IMAGING; FEMALE; GUADELOUPE; HALLUCINATIONS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PARKINSONIAN DISORDERS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 77957065418     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq162     Document Type: Article

References (45)

1. Apartis E, Gaymard B, Verhaeghe S, Roze E, Vidailhet M, Lannuzel A. Predominant cortical dysfunction in Guadeloupean parkinsonism. Brain 2008; 131: 2701-2709.
2. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000; 11: 805-821.
3. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005; 26: 839-851.
4. Blain CR, Barker GJ, Jarosz JM, Coyle NA, Landau S, Brown RG, et al. Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. Neurology 2006; 67: 2199-2205.
5. Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63: 81-86.
6. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75: 246-249.
7. Caparros-Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999; 354: 281-286.
8. Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, et al. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002; 125: 801-811.
9. Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, et al. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004; 88: 63-69.
10. Champy P, Melot A, Guerineau Eng V, Gleye C, Fall D, Hoglinger GU, et al. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupe. Mov Disord 2005; 20: 1629-1633.
11. Cordato NJ, Duggins AJ, Halliday GM, Morris JG, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain 2005; 128: 1259-1266.
12. Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997; 12: 767-771.
13. De Cock VC, Lannuzel A, Verhaeghe S, Roze E, Ruberg M, Derenne JP, et al. REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy. Sleep 2007; 30: 1026-1032.
14. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-1626.
15. Escobar-Khondiker M, Hollerhage M, Muriel MP, Champy P, Bach A, Depienne C, et al. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 2007; 27: 7827-7837.
16. Federico F, Simone IL, Lucivero V, De Mari M, Giannini P, Iliceto G, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62: 239-242. (Pubitemid 27117251)
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
18. Graber JJ, Staudinger R. Teaching NeuroImages: "Penguin" or "hummingbird" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009; 72: e81.
19. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
20. Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29: 280-289.
21. Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003; 210: 57-60.
22. Lannuzel A, Hoglinger GU, Verhaeghe S, Gire L, Belson S, Escobar- Khondiker M, et al. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes? Brain 2007; 130: 816-827.
23. Lannuzel A, Michel PP, Caparros-Lefebvre D, Abaul J, Hocquemiller R, Ruberg M. Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov Disord 2002; 17: 84-90.
24. Lannuzel A, Michel PP, Hoglinger GU, Champy P, Jousset A, Medja F, et al. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 2003; 121: 287-296.
25. Lannuzel A, Ruberg M, Michel PP. Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin. Mov Disord 2008; 23: 2122-2128.
26. Le Bihan D, Mangin JF, Poupon C, Clark CA, Pappata S, Molko N, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001; 13: 534-546.
27. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop. Neurology 1996; 47: 1-9.
28. Nicoletti G, Lodi R, Condino F, Tonon C, Fera F, Malucelli E, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129: 2679-2687.
29. Nicoletti G, Tonon C, Lodi R, Condino F, Manners D, Malucelli E, et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Mov Disord 2008; 23: 2370-2376.
30. Nilsson C, Markenroth Bloch K, Brockstedt S, Latt J, Widner H, Larsson EM. Tracking the neurodegeneration of parkinsonian disorders- a pilot study. Neuroradiology 2007; 49: 111-119.
31. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, et al. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 2008; 40: 1056-1063.
32. Oba H, Yagishita A, Terada H, Barkovich AJ, Kutomi K, Yamauchi T, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64: 2050-2055.
33. Ohshita T, Oka M, Imon Y, Yamaguchi S, Mimori Y, Nakamura S. Apparent diffusion coefficient measurements in progressive supranuclear palsy. Neuroradiology 2000; 42: 643-647.
34. Padovani A, Borroni B, Brambati SM, Agosti C, Broli M, Alonso R, et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2006; 77: 457-463.
35. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 2006; 129: 1040-1049.
36. Paviour DC, Price SL, Lees AJ, Fox NC. MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. J Neurol 2007; 254: 478-481.
37. Pierrot-Deseilligny C, Rivaud S, Pillon B, Fournier E, Agid Y. Lateral visually-guided saccades in progressive supranuclear palsy. Brain 1989; 112 (Pt 2): 471-487. (Pubitemid 19120155)
38. Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246: 214-221.
39. Righini A, Antonini A, De Notaris R, Bianchini E, Meucci N, Sacilotto G, et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004; 25: 927-932.
40. Rizzo G, Martinelli P, Manners D, Scaglione C, Tonon C, Cortelli P, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008; 131: 2690-2700.
41. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697-702.
42. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922-927.
43. Talairach J, Tournoux P. Co-Planar stereotaxic atlas of the human brain. New York: Thieme;1988.
44. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
45. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-1258